Racial Differences in Eligibility and Enrollment in a Smoking Cessation Clinical Trial

Health Psychology

Volumn 30, Issue 1, 2011, Pages 40-48

  King, Andrea C ^a   Cao, Dingcai ^a   Southard, Catherine C ^a   Matthews, Alicia ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

African American; Clinical trial; Eligibility; Racial differences; Smoking cessation

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH DISPARITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; RACE DIFFERENCE; SMOKING; SMOKING CESSATION; SUBSTANCE ABUSE; UNITED STATES; UNIVERSITY HOSPITAL; URBAN AREA;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; CHICAGO; ELIGIBILITY DETERMINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; YOUNG ADULT;

EID: 79951571247     PISSN: 02786133     EISSN: 19307810     Source Type: Journal    
DOI: 10.1037/a0021649     Document Type: Article

References (67)

1. Ahluwalia J.S., Harris K.J., Catley D., Okuyemi K.S., Mayo M.S. Sustained-release bupropion for smoking cessation in African Americans. Journal of the American Medical Association 2002, 288:468-474.
2. Ahluwalia J.S., McNagny S.E., Clark W.S. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. Journal of General Internal Medicine 1998, 13:1-8.
3. Audrain-McGovern J., Halbert C., Rodriguez D., Epstein L.H., Tercyak K.P. Predictors of participation in a smoking cessation program among young adult smokers. Cancer Epidemiology, Biomarkers, & Prevention 2007, 16:617.
4. Barbeau E.M., Krieger N., Soobader M.J. Working class matters: Socioeconomic disadvantage, race/ethnicity, gender and smoking in NHIS 2000. American Journal of Public Health 2004, 94:269-278.
5. Benowitz N.L. Smoking cessation trials targeted to racial and economic minority groups. Journal of General Internal Medicine 2002, 288:497-499.
6. Brodie M., Flournoy R.E., Altman D.E., Blendon R.J., Benson J.M., Rosenbaum M.D. Health information, the Internet, and the digital divide. Health Affairs 2000, 19:255-265.
7. Vital and Health Statistics, Series 10, Number 242, Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2008. Publication No. (PHS) 2010-1570 2009, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Washington, DC.
8. State-specific prevalence of current cigarette smoking among adults-United States, 2002. Morbidity and Mortality Weekly Review 2004, 52:1277-1280. Centers for Disease Control and Prevention.
9. Annual smoking: Attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. Morbidity and Mortality Weekly Review 2005, 54:625-628. Centers for Disease Control and Prevention.
10. Cigarette smoking among adults-United States, 2006. Morbidity and Mortality Weekly Review 2007, 56:1157-1161. Centers for Disease Control and Prevention.
11. Clark P.I., Gautham S., Gerson L.W. Effect of menthol cigarettes on biochemical markers of smoke exposure among black and white smokers. Chest 1996, 110:1194-1198.
12. Covey L.S., Glassman A.H., Stetner F. Naltrexone effects on short-term and long-term smoking cessation. Journal of Addictive Diseases 1999, 18:31-40.
13. Dahm J.L., Cook E., Baugh K., Wileyto E.P., Pinto A., Leone F., Schnoll R.A. Predictors of enrollment in a smoking cessation clinical trial after eligibility screening. Journal of the National Medical Association 2009, 101:451-455.
14. Dickerson D.L., Leeman R.F., Mazure C.M., O'Malley S.S. The inclusion of women and minorities in smoking cessation clinical trials: A systematic review. American Journal on Addictions 2009, 18:21-28.
15. Fagan P., King G., Lawrence D., Patrucci S.A., Robinson R.G., Banks D., Grana R. Eliminating tobacco-related health disparities: Directions for future research. American Journal of Public Health 2004, 94:211-217.
16. Fiore M.C., Jaén C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S.J., Wewers M.E. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline 2008, U.S. Department of Health and Human Services, Public Health Service, Rockville, MD.
17. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR Axis I disorders, research version, non-patient edition (SCID-I/NP) 1995, Biometrics Research, New York State Psychiatric Institute, New York.
18. Fitzgibbon M.L., Prewitt T.E., Blackman L.R., Simon P., Luke A., Keys L.C., Singh V. Quantitative assessment of recruitment efforts for prevention trials in two diverse black populations. Preventive Medicine 1998, 27:838-845.
19. Fu S.S., Kodl M.M., Joseph A.M., Hatsukami D.K., Johnson E.O., Breslau N., Bierut L. Racial/ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiology, Biomarkers, & Prevention 2008, 17:1640-1647.
20. Gandhi K.K., Foulds J., Steinberg M.B., Lu S.E., Williams J.M. Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic. International Journal of Clinical Practice 2009, 63:360-367.
21. Gariti P., Levin S., Whittingham T., Barou D., Kampman K.M., Lynch K., Alterman A. Why do those who request smoking treatment fail to attend the first appointment?. Journal of Substance Abuse Treatment 2008, 35:2-67.
22. Garrow J.S., Webster J. Quetelet's index (W/H2) as a measure of fatness. International Journal of Obesity 1985, 9:147-153.
23. Giovino G.A., Sidney S., Gfroerer J.C., O'Malley P.M., Allen J.A., Richter P.A. Epidemiology of menthol cigarette use. Nicotine & Tobacco Research 2004, 6:S67-S81.
24. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Reeves K.R. Varenicline, an αaβ2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. Journal of General Internal Medicine 2006, 296:47-55.
25. Harris K.J., Ahluwalia J.S., Catley D., Okuyemi K.S., Mayo M.S., Resnicow K. Successful recruitment of minorities into clinical trials: The Kick It at Swope project. Nicotine & Tobacco Research 2003, 5:575-584.
26. Heatherton T.F., Kozlowshi L.T., Frecker R.C., Fagerström K. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström tolerance questionnaire. British Journal of Addiction 1991, 86:1119-1127.
27. Hjalmarson A.I., Franzon M., Westin A., Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Archives of Internal Medicine 1994, 154:2567-2572.
28. Horner, M. J., Ries, L. A. G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., & Edwards, B. K. (Eds.). (2009). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Retrieved from http://seer.cancer.gov/csr/1975_2006/.
29. Hurt R.D., Sachs D.P., Gliver E.D., Offorf K.P., Johnston J.A., Dale L.C., Sullivan P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine 1997, 337:1195-1202.
30. Jeffries S.K., Choi W., Butler J., Harris K.J., Ahluwalia J.S. Strategies for recruiting African-American residents of public housing developments into a randomized controlled trial. Ethnicity & Disease 2005, 15:773-778.
31. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Reeves K.R. Efficacy of varenicline, an αaβ2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of General Internal Medicine 2006, 296:56-63.
32. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 1999, 340:685-691.
33. Characteristics of persons living with AIDS at the end of 1999 2001, Kaiser Family Foundation, Retrieved from statehealthfacts.org.
34. Kiefe C.I., Williams O.D., Lewis C.E., Allison J.J., Sekar P., Wagenknecht L.E. Ten-year changes in smoking among young adults: Are racial differences explained by socioeconomic factors in the CARDIA study?. American Journal of Public Health 2001, 91:213-218.
35. King, A. C., & Cao, D. (2010, February). Naltrexone effects on smoking cessation quit rates, urges, and weight gain: An examination of sex differences. Paper presentation at the annual conference of the Society for Research on Nicotine and Tobacco, Baltimore.
36. King, A. C., Cao, D., Southard, C., & Matthews, A. (2010, February). Racial disparities in screening and eligibility determination in a smoking cessation clinical trial. Paper presented at the annual conference of the Society for Research on Nicotine and Tobacco, Baltimore.
37. King A.C., de Wit H., Riley R.C., Cao D., Niaura R., Hatsukami D. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine & Tobacco Research 2006, 8:671-682.
38. King A.C., Sánchez-Johnsen L., Van Orman S., Cao D., Matthews A.K. A pilot community-based intensive smoking cessation intervention in African Americans: Feasibility, acceptability, and early outcome indicators. Journal of the National Medical Association 2008, 100:208-217.
39. King G., Polednak A., Bendel R.B., Vilsaint M.C., Nahata S.B. Disparities in smoking cessation between African Americans and Whites: 1990-2000. American Journal of Public Health 2004, 94:1965-1971.
40. Kreuter M.W., Lukwago S.N., Bucholtz R.D., Clark E.M., Sanders-Thompson V. Achieving cultural appropriateness in health promotion programs: Targeted and tailored approaches. Health Education & Behavior 2003, 30:133-146.
41. Lacey L.P., Manfredi C., Balch G., Warnecke R.B., Allen K., Edwards C. Social support in smoking cessation among black women in Chicago public housing. Public Health Reports 1993, 108:387-394.
42. Lee R.E., McGinnis K.A., Sallis J.F., Castro C.M., Chen A.H., Hickmann S.A. Active vs. passive methods of recruiting ethnic minority women to a health promotion program. Annals of Behavioral Medicine 1997, 19:378-384.
43. Lorence D.P., Park H., Fox S. Racial disparities in health information access: Resilience of the digital divide. Journal of Medical Systems 2006, 30:241-249.
44. Matthews A.K., Sánchez-Johnsen L., King A.C. Development of a culturally targeted smoking cessation intervention for African American smokers. Journal of Community Health 2009, 34:480-492.
45. Mazas C.A., Wetter D.W. Smoking cessation interventions among African Americans: Research needs. Cancer Control 2003, 10(5 Suppl):87-89.
46. Nollen N.S., Mayo M.S., Sanderson Cox L., Okuyemi K.S., Kaur H., Ahluwalia J.S. Predictors of quitting among African American light smokers enrolled in a randomized, placebo-controlled trial. Journal of General Internal Medicine 2006, 21:590-595.
47. O'Malley S.S., Cooney J.L., Krishnan-Sarin S., Dubin J.A., McKee S.A., Cooney N.L., Jatlow P. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine 2006, 166:667-674.
48. Pérez-Stable E.J., Herrera B., Jacob P., Benowitz N.L. Nicotine metabolism and intake in black and white smokers. Journal of General Internal Medicine 1998, 280:152-156.
49. Piper M.E., Fox B.J., Welsch S.K., Fiore M.C., Baker T.B. Gender and racial/ethnic differences in tobacco-dependence treatment: A commentary and research recommendations Nicotine & Tobacco Research 2001, 3(4):291-297.
50. Robles G.I., Singh-Franco D., Ghin H.L. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. Clinical Therapeutics 2008, 30:800-812.
51. Royce J.M., Hymowitz N., Corbett K., Hartwell T.D., Orlandi M.A. Smoking cessation factors among African Americans and Whites. American Journal of Public Health 1993, 83:220-226.
52. Schneider N.G., Olmstead R., Nilsson F., Mody F.V., Franzon M., Doan K. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo controlled trial. Addiction 1996, 91:1293-1306.
53. Shaya F.T., Gbaravor C.M., Huiwen K.Y., Agyeman-Dauh M., Saunders E. A perspective on African American participation in clinical trials. Contemporary Clinical Trials 2007, 28:213-217.
54. Shiffman S. Light and intermittent smokers: Background and perspective. Nicotine & Tobacco Research 2009, 11:122-125.
55. Shiffman S., Dresler C.M., Hajek P., Gilburt S.J., Targett D.A., Strahs K.R. Efficacy of a nicotine lozenge for smoking cessation. Archives of Internal Medicine 2002, 162:1267-1276.
56. Shiffman S., Rolf C.N., Hellebusch S.J., Gorsline J., Gorodetzky C.W., Chiang Y.K., Di Marino M.E. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 2002, 97:505-516.
57. Signorello L.B., Cai Q., Tarone R.E., McLaughlin J.K., Blot W.J. Racial differences in serum cotinine levels of smokers. Disease Markers 2009, 27:187-192.
58. Staffileno B.A., Coke L.A. Recruiting and retaining young, sedentary, hypertension-prone African American women in a physical activity intervention study. Journal of Cardiovascular Nursing 2006, 21:208-216.
59. Targonski P.V., Persky V.W., Orris P., Addington W. Trends in asthma mortality among African Americans and Whites in Chicago, 1968 through 1991. American Journal of Public Health 2005, 84:1830-1833. Illinois Department of Health.
60. Tobacco Burden in Illinois. Retrieved from http://www.idph.state.il.us/cancer/factsheets/burden.htm.
61. Tonnesen P., Norregaard J., Mikkelsen K., Jorgensen S., Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. Journal of General Internal Medicine 1993, 269:1268-1271.
62. Tonstad S., Tonnesen P., Hajk P., Williams K.E., Billing C.B., Reeves K.R. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. Journal of General Internal Medicine 2006, 296:64-71.
63. Chicago Community Area (CCA) Profiles 2000, U.S. Census Bureau, Census Data for the City of Chicago.
64. Wagenknecht L.E., Cutter G.R., Haley N.J., Sidney S., Manolio T.A., Hughes G.H., Jacobs D.R. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. American Journal of Public Health 1990, 80:1053-1060.
65. Webb M.S., Seigers D., Wood E.A. Recruiting African American smokers into intervention research: Relationships between recruitment strategies and participant characteristics. Research in Nursing & Health 2009, 32:86-95.
66. Wong G.Y., Wolter T.D., Croghan G.A., Croghan I.T., Offord K.P., Hurt R.D. A randomized trial of naltrexone for smoking cessation. Addiction 1999, 94:1227-1237.
67. Woods M.N., Harris K.J., Mayo M.S., Catley D., Scheibmeir M., Ahluwalia J.S. Participation of African Americans in a smoking cessation trial: A quantitative and qualitative study. Journal of the National Medical Association 2002, 94:609-618.